Recombinant human erythropoietin in sports: A review;Eritropoetina humana recombinante no esporte: Uma revisão

Revista Brasileira de Medicina do Esporte

Volumn 9, Issue 3, 2003, Pages 181-190

  de Almeida Bento, Rafael Maia ^a   Pinto Damasceno, Lúcia Menezes ^a,b   de Aquino Neto, Francisco Radler ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Cid Univ Ilha do Fundão   (Brazil)

Author keywords

Doping control; Epoetin; Erythropoietin; Peptidic hormones

Indexed keywords

COMPLEMENTARY DNA; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ATHLETE; DOPING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG SYNTHESIS; ERYTHROPOIESIS; HEADACHE; HEMODIALYSIS; HUMAN; INTRACRANIAL HYPERTENSION; KIDNEY FAILURE; MOLECULAR CLONING; MUSCLE TISSUE; NAUSEA; OXYGEN SUPPLY; PHOTOPHOBIA; PROTEIN SYNTHESIS; REVIEW; SCREENING TEST; SPORTS MEDICINE; URINARY EXCRETION; VOMITING;

EID: 0242331658     PISSN: 15178692     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1517-86922003000300006     Document Type: Review

References (106)

1. Adamson JW. Regulation of red blood cell production. Am J Med 1996; 101:S4-6.
2. Ekblom BT. Erythropoietin. In: Bahrke MS, Yesalis CE, editors. Performance-enhancing substances in sport and exercise. USA: Human Kinetics, 2002:101-7.
3. Choi D, Kim M, Park J. Erythropoietin: physico and biochemical analysis. J Chromatogr B 1996;687:189-99.
4. IOC Medical Commission. IOC list of prohibited classes of substances and prohibited methods. 2003 Olympic Movement Antidoping Code, Appendix A, International Olympic Committee, Lausane.
5. River L, Saugy M. Peptides hormones abuse in sport: state of the art in the detection of growth hormone and erythropoietin. J Toxicol-Toxin Reviews. In press 2003.
6. Catlin DH, Hatton CK. Use and abuse of anabolic and other drugs for athletic enhancement. Adv Intern Med 1991;36:399-424.
7. Magnani M, Corsi D, Bianchi M, Paiardini M, Galluzi L, Parisi A, et al. Monitoring erythropoietin abuse in athletes. Br J Haematol 1999;106: 260-1.
8. Gareau R, Brisson GR, Chénard C, Gagon MG, Audran M. Total fibrin and fibrinogen degradation products in urine: a possible probe to detect illicit users of the physical-performance enhancer erythropoietin? Horm Res 1995;44:189-92.
9. Skibeli GA, Nissen-Lie GA, Noreau P, Torjesen P, Hemmersbach P, Birkeland KI. Immuno-affinity extraction of erythropoietin from human serum by magnetic beads. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (6). Köln: Sport und Buch Strauß, 1998;313-29.
10. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular biology of the cell. 3rd ed. New York: Garland Publishing, 1994.
11. Rassier DE, Natali AJ, De Rose EH. Eritrocitemia induzida e dosagem sanguínea. Rev Bras Med Esporte 1995;1:11-5.
12. Oliveira MAB. Doping e coração. Rev SOCERJ 2000;13:53-60.
13. Constantinescu SN, Ghaffari S, Lodish HF. The erythropoietin receptor: structure activation and intracellular signal transduction. Trends Endocrinol Metab 1999;10:18-23.
14. Prchal JT, Semenza GL, Prchal J, Sokol L. Familial polycythemia. Science 1995;268:1831-2.
15. Dine G, Van Lierde, Rehn Y, Gillier N. Problèmes associés à l'usage de l'érythropoietin en milieu sportif. Immunoanal Biol Spéc 2001;16:235-43.
16. Produtos Roche Químicos e Farmacêuticos S.A. Recormon® Eritropoetina beta: anemia em câncer. Rio de Janeiro: Roche.
17. Miyake T, Kung CKH, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252:5558-64.
18. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:806-10.
19. Rendic S. Human recombinant erythropoietin (rHuEPO) - physiology and biochemistry. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (5). Köln: Sport und Buch Strauß, 1997;191-208.
20. Wide L, Bengtsson C. Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 1990;76:121-7.
21. Birkeland K I, Hemmersbach P. The future of doping control in athletes - Issues related to blood sampling. Sports Med 1999;28:25-33.
22. Suassuna JHR. Via de administração da eritropoetina. J Bras Nefrol 2000; 22:29-31.
23. Gurney CW, Wackman N, Vilmanowitz E. Studies on erythropoiesis. XVII. Some quantitative aspects of the erythropoietic response to erythropoietin. Blood 1961;17:531-46.
24. Goldberg MA. Erythropoiesis, erytropoietin, and iron metabolism in selective surgery: preoperative strategies for avoiding allogeneic blood exposure. Am J Surg 1995;179:S37-43.
25. Jansen JD, Madsen JK, Jansen LW. Comparison of dose requirement, serum erythropoietin, and blood pressure following intravenous and subcutaneous erythropoietin treatment in dialysis patients. Eur J Clin Pharmacol 1996;50:171-7.
26. Wendell RF, Waldman TA. The metabolism of erythropoietin in patients with anemia due to deficient erythropoiesis. J Clin Invest 1964;43:1348-54.
27. Jansen JD, Jansen LW, Madsen JK, Poulsen J. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 1995;54:111-6.
28. Nielsen OJ, Jord ME, Hirth P. The metabolism of recombinant erythropoietin in the isolated perfused rat liver. Liver 1990;10:343-9.
29. Dunn J, Markham A. Epoietin beta, a review of its pharmacological properties and clinical use in the management of anemia with chronic renal failure. Drugs 1996;5:299-318.
30. Skibeli V, Nielsen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001;98:3626-34.
31. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100: 79-89.
32. Helstenson CE, Macres M, Katz AS, Schnieders JR, Watanabe M, Sobota JT, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-12.
33. Uji Y, Hirashima K, Hirasawa Y, Iwasaki Y, Tohira Y, Mizuno K. A phase I study of recombinant human erythropoietin in healthy volunteers-multiple dosing study. New drugs physicians 1989;26:29-44.
34. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990;29:709-13.
35. Flaharty KK, Caro J, Erslev A. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990;47:557-64.
36. Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneous administered erythropoietin in maintance hemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol 1992;12:68-72.
37. Cazzola M. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica 2002;85:561-3.
38. Guezennec Ch-Y. Le dopage: efficacité, conséquences, prévention. Ann Endocrinol (Paris) 2001;62:33-41.
39. http://www.ausport.gov.au/ais/physiology/epoback.htm
40. Birkeland KI, Donike M, Ljungqvist A, Fagerhol M, Jansen J, Hammersbach P, et al. Blood sampling in doping control - First experiences from regular testing in athletics. Int J Sports Med 1997;18:8-12.
41. Ashenden M. A strategy to deter blood doping in sport. Haematologica 2002;87:225-34.
42. Simon TL. Induced erythrocythemia and athletic performance. Semin Hematol 1994;31:128-33.
43. Catlin DH, Murray TH. Performance-enhancing drugs, fair competition, and olympic sport. JAMA 1996;276:231-7.
44. Browne A, Lachance V, Pipe A. The ethics of blood testing as an element of doping control sport. Med Sci Sports Exerc 1999;31:497-501.
45. Scott WC. The abuse of erythropoietin to enhance athletic performance. JAMA 1990;264:1660.
46. Wadler GI. Drug use update. Sports Med 1994;78:439-55.
47. Adamson JW. Recombinant erythropoietin to improve athletic performance. N Engl J Med 1991;324:698-9.
48. Gauthier J. Effects cardiovasculaires du dopage. Ann Cardiol Angeiol (Paris) 2001;50293:8.
49. Aquino Neto FR. O papel do atleta na sociedade e o controle de dopagem no esporte. Rev Bras Med Esporte 2001;7:1-11.
50. Clyne N, Berglund B, Egberg N. Treatment with recombinant human erythropoietin induces a moderate rise in hematocrit and thrombin antithrombin in healthy subjects. Thromb Res 1995;79:125-9.
51. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
52. Cazzola M. Further concerns about the medical risks of blood doping. Haematologica 2002;87:232.
53. Gareau R, Audran M, Baynes RD, Flowers CH, Duvallet A, Senécal L, et al. Erythropoietin abuse in athletes. Nature 1996;380:113.
54. Thein LA, Thein JM, Landry GL. Ergogenic aids. Phys Ther 1995;75: 426-39.
55. Zorpette G. All doped up - and going for the gold. Sci Am 2000;282: 20-2.
56. The Lancet (editorial). Peddling drugs to the pedal pushers. Lancet 1998; 352:415.
57. Jarvis CA. Tour de France. Br J Sport Med 1999;33:142-3.
58. Lage JMM, Panizo C, Masdeu J, Rocha E. Cyclist's doping associated with cerebral sinus thrombosis. Neurology 2002;58:665.
59. Jenkins P. Doping in sport. Lancet 2002;360:99-100.
60. http://www.wada-ama.org
61. Berglund B, Hemmingsson P, Birgegard G. Detection of autologous blood transfusions in cross-country skiers. Int J Sport Med 1987;8:66-70.
62. Casoni I, Ricci G, Ballarin E, Borsetto C, Grazzi G, Guglielmini C, et al. Hematological indices of erythropoietin administration in athletes. Int J Sport Med 1993;14:307-11.
63. Mottram DR. Banned drugs in sport - Does the International Olympic Committee (IOC) list need updating? Sports Med 1999;27:1-10.
64. Davey G, Nerurkar R, Doping in sport. Lancet 1998;352:1781-2.
65. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power. Scand J Med Sci Sports 1991;1:88-93.
66. Zorzoli M, Schattenberg L, Mangin P. The medical monitoring of the International Cycling Union. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (8). Köln: Sport und Buch Strauß, 2000;83-7.
67. Breymann C, Rohling R, Krafft A, Huch A, Huch R. "Blood doping" with recombinant erythropoietin (rHuEPO) and assessment of functional iron deficiency in healthy volunteers. Br J Haematol 2000;108:883-4.
68. Saris WHM, Senden JMG, Brouns F. What is a normal red-blood cell mass for professional cyclists? Lancet 1998;352:1758.
69. Russell G, Gore JC, Ashenden MJ, Parisotto R, Hahn AG. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur J Appl Physiol 2002;86:442-9.
70. Souillard A, Audran M, Bressolle F, Gareau R, Duvallet A, Chanal JL. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br J Clin Pharmacol 1996;42:355-64.
71. Abbott A. What a price the Olympian ideal? Nature 2000;407:124-7.
72. Dore F, Bonfigli S, Gaviano E, Pardini S, Longinotti M. Serum transferrin receptor levels in patients with talessemia intermedia during rHuEPO administration. Haematologica 1996;81:37-9.
73. Gareau R, Gagnon MG, Thellend C, Chénard C, Audran M, Chanal J-L, et al. Transferrin soluble receptor: a possible probe for detection of erythropoietin abuse by athletes. Horm Metab Res 1994;26:311-2.
74. Birkeland KI, Fiskum K, Bjerke B, Haug E, Hemmersbach P. Physiological and non-physiological variations in serum levels of soluble transferrin receptor - Implications for use as indicator of doping with rHuEPO. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (7). Köln: Sport und Buch Strauß, 1999;289-90.
75. Brisson GR, Gareau R, Ayotte C. Induced haemostatic shift: a possible tool for EPO detection. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (1). Köln: Sport und Buch Strauß, 1993;185-90.
76. Birkeland KI, Stray-Gundersen J, Hammersbach P, Hallen J, Haug E, Bahr R. Effect of rHuEPO administration on levels of sTfR and cycling performance. Med Sci Sports Exerc 2000;32:1238-43.
77. Magnani M, Corsi D, Bianchi M, Paiardini M, Galluzzi L, Gargiullo E, et al. Identification of blood erythroid markers useful in revealing erythropoitin abuse in athletes. Blood Cells Mol Dis 2001;27:559-71.
78. Robinson N, Marti B, Mangin P, Saugy M. Secondary markers of erythroid activity: any use for doping diagnosis in professional cyclists? In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (8). Köln: Sport und Buch Strauß, 2000; 79-82.
79. Bonnaire Y. Les problèmes actuels du controle antidopage équin. Revue Fr Lab 1999;310:73-6.
80. Kearns CF, Lenhart JA, McKeever KH. Cross-reactivity between human erythropoietin antibody and horse erythropoietin. Electrophoresis 2000;21:1454-7.
81. Gareau R, Brisson GR, Ayotte C, Dubé J, Caron C. Erythropoietin doping in athletes: possible detection through measurement of van Willebrand factor and D-dimer activity? Thromb Haemost 1992;68:481-2.
82. Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, et al. A novel method utilizing markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000;85:564-72.
83. Parisotto R, Wu M, Ashenden MJ, Emslie KR, Gore CJ, Howe C, et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoisis. Haematologica 2001;86:128-37.
84. Audran M, Gareau R, Matechi S, Durand F, Chenard C, Sicart M-T, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc 1999; 31:639-45.
85. Yang SM, Wang XB, Fang ZL, Wang SH, Qin Y, Yi MQ, et al. Observation on hematology and biochemistry of six Chinese following rHuEPO administration. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (5). Köln: Sport und Buch Strauß, 1997;215-21.
86. Breidbach A, Schänzer W. Individual reference ranges for serum erythropoietin (sEPO) - A possible approach to detect misuse. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (6). Köln: Sport und Buch Strauß, 1998;301-10.
87. Hemmersbach P, Stray-Gundersen J, Hallén J, Haug E, Bahr R, Birkeland KI. The effects of suprafisiological doses of erythropoietin in healthy young men. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (6). Köln: Sport und Buch Strauß, 1998;311-2.
88. Bialas B, Breidbach A, Schänzer W. Individual reference ranges for serum erythropoietin (sEPO) - Part II: Influence of long distance flying. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (7). Köln: Sport und Buch Strauß, 1999; 301-9.
89. Bialas B, Schwenke D, Schänzer W, Mülller RK. Diurnal variation of indirect parameters for the detection of recombinant human abuse in athletes. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (9). Köln: Sport und Buch Strauß, 2001;311-6.
90. Emslie KR, Howe C, Trout G. Measurement of urinary erythropoietin levels in athletes. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (7). Köln: Sport und Buch Strauß, 1999;291-9.
91. Birkeland KI, Hemmersbach P, Haug E. Blood sampling in doping control - Which new information may be obtained? In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (2). Köln: Sport und Buch Strauß, 1994;9-14.
92. Breibach A, Platen P, Schänzer W. Erythropoietin - Influence of strain and application on concentrations in blood and urine. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (4). Köln: Sport und Buch Strauß, 1996;319-21.
93. Kazlauskas R. Sydney Olympics 2000: an overview. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (9). Köln: Sport und Buch Strauß, 2001;167-77.
94. Trout GJ, Emslie KR, Howe C, Kazlauskas R, Lasne F. An overview of testing for EPO at the Sydney 2000 Olympic Games and beyond. In: Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors. Recent advances in doping analysis (9). Köln: Sport und Buch Strauß, 2001; 191-200.
95. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature 2000; 405:635.
96. Birchard K. Past, present, and future of drug abuse at the Olympics. Lancet 2000;356:1008.
97. http://www.cafdis-antidoping.net/en/article.asp?articleid=273&page=1.
98. http://www.aranesp.com
99. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84:3-10.
100. Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharm Ther 2002;72: 546-55.
101. http://www.dshs-koeln.de/biochemie/rubriken/00_home/00_dar.html
102. http://www.webrun.com.br/corridasderua/index.php?destinocomum= noticia_mostra&id_noticias=635&id_eventos=
103. http://www.cbat.org.br
104. Cifuentes A, Moreno-Arribas MV, Frutos M, Díez-Masa JC. Capillary isoelectric focusing of erythropoietin glycoforms and its comparison with flat-bed isoelectric focusing and capillary zone electrophoresis. J Chromatogr A 1999;830:453-63.
105. Stanley SMR, Poljak A. Matrix-assisted laser-desorption time of flight ionization and high-performance liquid chromatography-electrospray ionization mass spectral analysis of two glycosilated recombinant epoetins. J Chromatogr. In press 2003.
106. Adam D. Gene therapy may be up to speed for cheats at 2008 Olympics. Nature 2001;414:569-70.